Downloads: 156

Files in This Item:
File Description SizeFormat 
bioengineering4030078.pdf4.74 MBAdobe PDFView/Open
Title: Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
Authors: Yasunaga, Masahiro
Manabe, Shino
Tsuji, Atsushi
Furuta, Masaru
Ogata, Koretsugu
Koga, Yoshikatsu
Saga, Tsuneo  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-7801-9316 (unconfirmed)
Matsumura, Yasuhiro
Author's alias: 佐賀, 恒夫
Keywords: ADC (antibody-drug conjugate)
DDS (drug delivery system)
molecular imaging
antibody delivery
controlled release
PET (positron emission tomography)
MSI (mass spectrometry imaging)
Issue Date: 17-Sep-2017
Publisher: MDPI AG
Journal title: Bioengineering
Volume: 4
Issue: 3
Thesis number: 78
Abstract: Antibody-drug conjugate (ADC), as a next generation of antibody therapeutics, is a combination of an antibody and a drug connected via a specialized linker. ADC has four action steps: systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells, such as through drug delivery system (DDS) drugs. An antibody with a size of about 10 nm has the same capacity for passive targeting as some DDS carriers, depending on the EPR effect. In addition, some antibodies are capable of active targeting. A linker is stable in the bloodstream but should release drugs efficiently in the tumor cells or their microenvironment. Thus, the linker technology is actually a typical controlled release technology in DDS. Here, we focused on molecular imaging. Fluorescent and positron emission tomography (PET) imaging is useful for the visualization and evaluation of antibody delivery in terms of passive and active targeting in the systemic circulation and in tumors. To evaluate the controlled release of the ADC in the targeted area, a mass spectrometry imaging (MSI) with a mass microscope, to visualize the drug released from ADC, was used. As a result, we succeeded in confirming the significant anti-tumor activity of anti-fibrin, or anti-tissue factor-ADC, in preclinical settings by using DDS and molecular imaging
Rights: © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
URI: http://hdl.handle.net/2433/233663
DOI(Published Version): 10.3390/bioengineering4030078
PubMed ID: 28952557
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.